Clinical trial · no report yet · Phase 3
PRISM-1
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- NCT06608927 ↗
- Active, not recruiting
- Arcus Biosciences, Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Quemliclustat; Placebo; Nab-paclitaxel; Gemcitabine
- Arms
- Arm A (Experimental Arm) · Experimental
- Arm B (Comparator Arm) · Placebo comparator
- Enrollment
- 610 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Arcus Biosciences, Inc. with Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 13, 2024
- Primary completion
- Nov 30, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06608927 · updated Sep 29, 2026